Type 2 diabetes mellitus is a growing health problem across the world. Thiazolidinediones, a new class of oral antidiabetic agents, appear to be ideally suited for the treatment of this disease. The examination of the clinical efficacy of different thiazolidinediones has been extensive. This review summarizes the current state of the cut concerning the clinical use of different thiazolidinediones, starting from the first synthetic thiazolidinediones to the recently developed glitazones. A main focus of this review is the description of the chemistry of these compounds including their synthesis.
Keywords: Thiazolidinediones, antidiabetic compounds, glitazones, compounds, diabetes mellitus, hyperglycemia, cell, PPAR receptor, Troglitazone, Rezulin, alanine aminotransferase, hepatotoxicity, carboxylic acids, thiourea, hypolipidemic activity, Ciglitazone, diazonium chloride, englitazone, sodium methoxide, benzofuran thiazolidinediones, sulfonylureas, metformin, glucosidase inhibitors, vinylarene, diazonium bromide, bromopropionate, Rosiglitazone, Netoglitazone, Rivoglitazone, lobeglitazone